Frost & Sullivan Applaud AxoGen's Proprietary Process for Producing Decellularized Nerve Allografts

Frost & Sullivan Applaud AxoGen'sFrost & Sullivan Applaud AxoGen's Proprietary Process for Producing Decellularized Nerve Allografts PR Newswire MOUNTAIN VIEW, California, Jan. 6, 2014 -- AxoGen is the only regenerative medicine company that is completely focused on peripheral nerve repair Based on its recent analysis of the peripheral nerve repair market, Frost & Sullivan recognizes AxoGen, Inc. with the 2013 North American Frost & Sullivan New Product Innovation Leadership Award for developing the Avance® Nerve Graft, a decellularized nerve allograft. Avance® Nerve Graft is the only commercially available processed nerve allograft product available in the United States and is unique because it is free of all the cells and cellular debris from the donor, retaining only the extracellular matrix. The removal of the donor's nerve cells from the allograft makes Avance® a superior grafting option, as it eliminates the strong and prolonged immune response from the patient's body, which can be so severe that the body rejects the transplant. The second innovative feature of Avance® is its intact three-dimensional (3D) internal architecture of the extracellular matrix, which enables guided cellular regrowth. Competing products, which are hollow tube conduits, have an enclosed environment for cell migration but provide only an approximate alignment of the regenerating nerve fibers.